Ryanair Holdings plc. (RYAAY - Free Report) announced that it has amended the terms of a €700-million stock repurchase program to limit the number of British shareholders in the company. Through this move, the company aims to remain EU-owned majorly so as to comply with the licensing and flight rights. The €700-million buyback program commenced on May 21, 2019 and is expected to run for the next 9-12 months.
Earlier in March, Ryanair came to a resolution by virtue of which all shares held by non-EU shareholders (including British shareholders after Brexit) will be considered as "restricted shares", i.e, they will not be entitled to attend, speak or vote at company meetings.
Per the amended agreement, the airline will allow shares to be repurchased via block trades from EU shareholders. In the event of a no-deal Brexit, block repurchases from UK shareholders will lower the number of shares held by non-EU shareholders. Consequently, the amendment should reduce the time period for which the above-mentioned resolutions need to be in place.
Zacks Rank & Key Picks
Ryanair carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the same space are Air China Ltd. (AIRYY - Free Report) , SkyWest, Inc. (SKYW - Free Report) and United Continental Holdings, Inc. (UAL - Free Report) . While Air China sports a Zacks Rank #1 (Strong Buy), SkyWest and United Continental carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of Air China, SkyWest and United Continental have gained more than 12%, 27% and 2%, respectively, in the past six months.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>